FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092327096> ?p ?o ?g. }

• W2092327096 abstract "Background Sickle cell disease (SCD) is a recessive genetic blood disorder, caused by a mutation in the β-globin gene. For children with SCD, the risk of stroke is estimated to be up to 250 times higher than in the general childhood population. Transcranial Doppler (TCD) ultrasonography is a non-invasive technique which measures local blood velocity in the proximal portions of large intracranial arteries. Screening with TCD ultrasonography identifies individuals with high cerebral blood velocity; these children are at the highest risk of stroke. A number of primary stroke prevention strategies are currently used in clinical practice in the UK including blood transfusion, treatment with hydroxycarbamide and bone marrow transplantation (BMT). No reviews have yet assessed the clinical effectiveness and cost effectiveness of primary stroke prevention strategies in children with SCD identified to be at high risk of stroke using TCD ultrasonography. Objective To assess the clinical effectiveness and cost-effectiveness of primary stroke prevention treatments for children with SCD who are identified (using TCD ultrasonography) to be at high risk of stroke. Data sources Electronic databases were searched from inception up to May 2011, including the Cochrane Database of Systematic Reviews (CDSR), the Cochrane Central Register of Controlled Trials (CENTRAL), the Database of Abstracts of Reviews of Effects (DARE), EMBASE, the Health Technology Assessment (HTA) database, ISI Web of Science Proceedings, ISI Web of Science Citation Index, the NHS Economic Evaluation Database (NHS EED) and MEDLINE. Review methods The assessment was conducted according to accepted procedures for conducting and reporting systematic reviews and economic evaluations. A de novo Markov model was developed to determine the cost-effectiveness of TCD ultrasonography and blood transfusion, where clinically appropriate, in patients with SCD. Results Two randomised controlled trials met the inclusion criteria involving a study population of 209 participants. One compared blood transfusion with standard care for children who are identified as being at high risk of stroke using TCD ultrasonography. In this trial, one patient in the transfusion group had a stroke (1/63) compared with 11 children in the standard care group (11/67). The other trial assessed the impact of halting chronic transfusion in patients with SCD. Sixteen patients in the transfusion-halted group had an event (16/41) (two patients experienced stroke and 14 reverted to abnormal TCD velocity); there were no events in the continued-transfusion group (0/38). No meta-analyses of these trials were undertaken. No relevant economic evaluations were identified for inclusion in the review. The de novo modelling suggests that blood transfusions plus TCD scans (compared with just TCD scans) for patients with SCD at high risk of stroke, aged ≥ 2 years, may be good value for money. The intervention has an incremental cost-effectiveness ratio of £24,075 per quality-adjusted life-year gained, and helps avoid 68 strokes over the lifetime of a population of 1000 patients. The intervention costs an additional £13,751 per patient and generates 0.6 extra years of life in full health per patient. The data available for the economic analysis are limited. Sensitivity analyses and validation against existing data and expert opinion provide some reassurance that the conclusion of the model is reliable but further research is required to validate these findings. Limitations The main limitations relate to the availability of published clinical data; no completed randomised controlled trials were identified which evaluated the efficacy of either BMT or hydroxycarbamide for primary stroke prevention. Both the clinical and cost data available for use in the economic analysis are limited. Sensitivity analyses and validation against existing data and expert opinion provide some reassurance that the conclusions of the model are reliable, but further research is required to validate these findings. Conclusions The use of TCD ultrasonography to identify children at high risk of stroke, and treating these children with prophylactic blood transfusions, appears to be both clinically effective and cost-effective compared with TCD ultrasonography only. However, given the limitations in the data available, further research is required to verify this conclusion. Several research recommendations can be proposed from this review. Clinically, more research is needed to assess the effects and optimal duration of long-term blood transfusion and the potential role of hydroxycarbamide in primary stroke prevention. From an economics perspective, further research is required to generate more robust data on which to base estimates of cost-effectiveness or against which model outputs can be calibrated. More data are required to explain how utility weights vary with age, transfusions and strokes. Research is also needed around the cost of paediatric stroke in the UK. Study registration PROSPERO CRD42011001496. Funding The National Institute for Health Research Health Technology Assessment programme." @default.
• W2092327096 created "2016-06-24" @default.
• W2092327096 creator A5011624664 @default.
• W2092327096 creator A5036356724 @default.
• W2092327096 creator A5041932491 @default.
• W2092327096 creator A5044957715 @default.
• W2092327096 creator A5050582071 @default.
• W2092327096 creator A5064023860 @default.
• W2092327096 creator A5068763092 @default.
• W2092327096 creator A5079590143 @default.
• W2092327096 creator A5085078280 @default.
• W2092327096 date "2012-11-01" @default.
• W2092327096 modified "2023-10-16" @default.
• W2092327096 title "The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation." @default.
• W2092327096 cites W127158871 @default.
• W2092327096 cites W1272191569 @default.
• W2092327096 cites W14052386 @default.
• W2092327096 cites W1498156640 @default.
• W2092327096 cites W1508585281 @default.
• W2092327096 cites W1582190272 @default.
• W2092327096 cites W158331737 @default.
• W2092327096 cites W1593173821 @default.
• W2092327096 cites W1597151660 @default.
• W2092327096 cites W1781374319 @default.
• W2092327096 cites W1877283940 @default.
• W2092327096 cites W1963845367 @default.
• W2092327096 cites W1975951312 @default.
• W2092327096 cites W1976293536 @default.
• W2092327096 cites W1978242664 @default.
• W2092327096 cites W1983093735 @default.
• W2092327096 cites W1984789764 @default.
• W2092327096 cites W1985305121 @default.
• W2092327096 cites W1992575642 @default.
• W2092327096 cites W1994951969 @default.
• W2092327096 cites W2000643072 @default.
• W2092327096 cites W2000685309 @default.
• W2092327096 cites W2002358091 @default.
• W2092327096 cites W2008700591 @default.
• W2092327096 cites W2010403938 @default.
• W2092327096 cites W2024134480 @default.
• W2092327096 cites W2026796607 @default.
• W2092327096 cites W2029506470 @default.
• W2092327096 cites W2031039743 @default.
• W2092327096 cites W2031113061 @default.
• W2092327096 cites W2032423016 @default.
• W2092327096 cites W2037319363 @default.
• W2092327096 cites W2041726006 @default.
• W2092327096 cites W2046401589 @default.
• W2092327096 cites W2050065017 @default.
• W2092327096 cites W2052847251 @default.
• W2092327096 cites W2053166287 @default.
• W2092327096 cites W2053324525 @default.
• W2092327096 cites W2056468334 @default.
• W2092327096 cites W2065319640 @default.
• W2092327096 cites W2069201334 @default.
• W2092327096 cites W2074022434 @default.
• W2092327096 cites W2081040380 @default.
• W2092327096 cites W2083481160 @default.
• W2092327096 cites W2098388627 @default.
• W2092327096 cites W2100055196 @default.
• W2092327096 cites W2103031455 @default.
• W2092327096 cites W2104949213 @default.
• W2092327096 cites W2107128024 @default.
• W2092327096 cites W2110141704 @default.
• W2092327096 cites W2111221288 @default.
• W2092327096 cites W2117045187 @default.
• W2092327096 cites W2125435699 @default.
• W2092327096 cites W2127432854 @default.
• W2092327096 cites W2134196875 @default.
• W2092327096 cites W2151456055 @default.
• W2092327096 cites W2151664585 @default.
• W2092327096 cites W2153316175 @default.
• W2092327096 cites W2159004505 @default.
• W2092327096 cites W2159010777 @default.
• W2092327096 cites W2160308620 @default.
• W2092327096 cites W2164654252 @default.
• W2092327096 cites W2172177100 @default.
• W2092327096 cites W2322074970 @default.
• W2092327096 cites W2322343762 @default.
• W2092327096 cites W2334263927 @default.
• W2092327096 cites W2338865912 @default.
• W2092327096 cites W3109486178 @default.
• W2092327096 cites W3135185800 @default.
• W2092327096 cites W2141832047 @default.
• W2092327096 cites W2314213298 @default.
• W2092327096 cites W2338924885 @default.
• W2092327096 cites W3144957394 @default.
• W2092327096 doi "https://doi.org/10.3310/hta16430" @default.
• W2092327096 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4780999" @default.
• W2092327096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23140544" @default.
• W2092327096 hasPublicationYear "2012" @default.
• W2092327096 type Work @default.
• W2092327096 sameAs 2092327096 @default.
• W2092327096 citedByCount "28" @default.
• W2092327096 countsByYear W20923270962014 @default.
• W2092327096 countsByYear W20923270962015 @default.
• W2092327096 countsByYear W20923270962016 @default.
• W2092327096 countsByYear W20923270962017 @default.
• W2092327096 countsByYear W20923270962018 @default.
• W2092327096 countsByYear W20923270962019 @default.

• next